Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial

M. T. Huizing, J. B. Vermorken, H. Rosing, W. W Ten Bokkel Huinink, I. Mandjes, H. M. Pinedo, J. H. Beijnen

Research output: Contribution to journalArticle

Abstract

Background: Hepatic metabolism and biliary clearance play pivotal roles in the disposition of the anticancer drug paclitaxel. 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and 6-a,3′-p-dihydroxypaclitaxel were the major metabolic products of paclitaxel found in human bile. Recently, these metabolic products were detected in human plasma. The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support. Patients and methods: Nine patients were entered into this study in which paclitaxel was administered at the relatively high dose of 250 mg/m2 during a 3-hour infusion. G-CSF was administered daily subcutaneously (s.c.) on days 2 to 19 following chemotherapy. Analysis of paclitaxel and metabolite concentrations was performed by a new highly sensitive reversed-phase high performance liquid chromato-graphic (HPLC) assay. Results: The dose-limiting toxicity in this study was cumulative neurotoxicity. One patient had a partial response and 2 patients had mixed responses of their skin metastases.Relatively low peak plasma concentration (Cmax) with mean values of 6.91 μmol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 μmol/L.h (range 14.88 to 40.57), were observed. The total body clearance was 16.99 L/h (range, 10.25 to 27.39). The pharmacokinetic parameter for the prediction of leuko-neutropenia, the duration of the plasma concentration above the threshold of 0.1 μmol/L (T>0.1 μM), was 19.72 h (range 10.54 to 26.31). The three major metabolites detected in human plasma were identified as 6-α-hydroxy-paclitaxel, 3′-p-hydroxypaclitaxel and 6-α,3′-p-dihydroxy-paclitaxel. Cmax and AUC values of these metabolites are reported. Conclusions: The three main metabolic products of paclitaxel in human plasma are 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and the dihydroxymetabolite 6-a,3′-p-di-hydroxypaclitaxel. Two patients with liver function disturbances showed a tendency to higher paclitaxel and 6-ct-hydroxypaclitaxel AUC levels, with more pronounced neuropathy.

Original languageEnglish (US)
Pages (from-to)699-704
Number of pages6
JournalAnnals of Oncology
Volume6
Issue number7
StatePublished - Sep 1995
Externally publishedYes

Fingerprint

Pharmacokinetics
Anthracyclines
Metabolites
Paclitaxel
Plasma (human)
Refractory materials
Therapy
Cancer
Plasma
Breast Neoplasms
Plasmas
Dose
Neoplasms
Clearance
Mean Value
Range of data
Area Under Curve
Chemotherapy
Therapeutics
Metabolism

Keywords

  • Anthracycline
  • Breast cancer
  • Hydroxylated metabolites
  • Paclitaxel (Taxol®)
  • Pharmacokinetics
  • Resistance

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion : A European Cancer Centre (ECC) trial. / Huizing, M. T.; Vermorken, J. B.; Rosing, H.; Huinink, W. W Ten Bokkel; Mandjes, I.; Pinedo, H. M.; Beijnen, J. H.

In: Annals of Oncology, Vol. 6, No. 7, 09.1995, p. 699-704.

Research output: Contribution to journalArticle

Huizing, M. T. ; Vermorken, J. B. ; Rosing, H. ; Huinink, W. W Ten Bokkel ; Mandjes, I. ; Pinedo, H. M. ; Beijnen, J. H. / Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion : A European Cancer Centre (ECC) trial. In: Annals of Oncology. 1995 ; Vol. 6, No. 7. pp. 699-704.
@article{55ca65b914594dff8aa23b40e32625fe,
title = "Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial",
abstract = "Background: Hepatic metabolism and biliary clearance play pivotal roles in the disposition of the anticancer drug paclitaxel. 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and 6-a,3′-p-dihydroxypaclitaxel were the major metabolic products of paclitaxel found in human bile. Recently, these metabolic products were detected in human plasma. The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support. Patients and methods: Nine patients were entered into this study in which paclitaxel was administered at the relatively high dose of 250 mg/m2 during a 3-hour infusion. G-CSF was administered daily subcutaneously (s.c.) on days 2 to 19 following chemotherapy. Analysis of paclitaxel and metabolite concentrations was performed by a new highly sensitive reversed-phase high performance liquid chromato-graphic (HPLC) assay. Results: The dose-limiting toxicity in this study was cumulative neurotoxicity. One patient had a partial response and 2 patients had mixed responses of their skin metastases.Relatively low peak plasma concentration (Cmax) with mean values of 6.91 μmol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 μmol/L.h (range 14.88 to 40.57), were observed. The total body clearance was 16.99 L/h (range, 10.25 to 27.39). The pharmacokinetic parameter for the prediction of leuko-neutropenia, the duration of the plasma concentration above the threshold of 0.1 μmol/L (T>0.1 μM), was 19.72 h (range 10.54 to 26.31). The three major metabolites detected in human plasma were identified as 6-α-hydroxy-paclitaxel, 3′-p-hydroxypaclitaxel and 6-α,3′-p-dihydroxy-paclitaxel. Cmax and AUC values of these metabolites are reported. Conclusions: The three main metabolic products of paclitaxel in human plasma are 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and the dihydroxymetabolite 6-a,3′-p-di-hydroxypaclitaxel. Two patients with liver function disturbances showed a tendency to higher paclitaxel and 6-ct-hydroxypaclitaxel AUC levels, with more pronounced neuropathy.",
keywords = "Anthracycline, Breast cancer, Hydroxylated metabolites, Paclitaxel (Taxol{\circledR}), Pharmacokinetics, Resistance",
author = "Huizing, {M. T.} and Vermorken, {J. B.} and H. Rosing and Huinink, {W. W Ten Bokkel} and I. Mandjes and Pinedo, {H. M.} and Beijnen, {J. H.}",
year = "1995",
month = "9",
language = "English (US)",
volume = "6",
pages = "699--704",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion

T2 - A European Cancer Centre (ECC) trial

AU - Huizing, M. T.

AU - Vermorken, J. B.

AU - Rosing, H.

AU - Huinink, W. W Ten Bokkel

AU - Mandjes, I.

AU - Pinedo, H. M.

AU - Beijnen, J. H.

PY - 1995/9

Y1 - 1995/9

N2 - Background: Hepatic metabolism and biliary clearance play pivotal roles in the disposition of the anticancer drug paclitaxel. 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and 6-a,3′-p-dihydroxypaclitaxel were the major metabolic products of paclitaxel found in human bile. Recently, these metabolic products were detected in human plasma. The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support. Patients and methods: Nine patients were entered into this study in which paclitaxel was administered at the relatively high dose of 250 mg/m2 during a 3-hour infusion. G-CSF was administered daily subcutaneously (s.c.) on days 2 to 19 following chemotherapy. Analysis of paclitaxel and metabolite concentrations was performed by a new highly sensitive reversed-phase high performance liquid chromato-graphic (HPLC) assay. Results: The dose-limiting toxicity in this study was cumulative neurotoxicity. One patient had a partial response and 2 patients had mixed responses of their skin metastases.Relatively low peak plasma concentration (Cmax) with mean values of 6.91 μmol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 μmol/L.h (range 14.88 to 40.57), were observed. The total body clearance was 16.99 L/h (range, 10.25 to 27.39). The pharmacokinetic parameter for the prediction of leuko-neutropenia, the duration of the plasma concentration above the threshold of 0.1 μmol/L (T>0.1 μM), was 19.72 h (range 10.54 to 26.31). The three major metabolites detected in human plasma were identified as 6-α-hydroxy-paclitaxel, 3′-p-hydroxypaclitaxel and 6-α,3′-p-dihydroxy-paclitaxel. Cmax and AUC values of these metabolites are reported. Conclusions: The three main metabolic products of paclitaxel in human plasma are 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and the dihydroxymetabolite 6-a,3′-p-di-hydroxypaclitaxel. Two patients with liver function disturbances showed a tendency to higher paclitaxel and 6-ct-hydroxypaclitaxel AUC levels, with more pronounced neuropathy.

AB - Background: Hepatic metabolism and biliary clearance play pivotal roles in the disposition of the anticancer drug paclitaxel. 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and 6-a,3′-p-dihydroxypaclitaxel were the major metabolic products of paclitaxel found in human bile. Recently, these metabolic products were detected in human plasma. The pharmacokinetics of paclitaxel and its metabolites were investigated in anthracycline-resistant breast cancer patients treated with high-dose paclitaxel and granulocyte colony-stimulating factor (G-CSF) support. Patients and methods: Nine patients were entered into this study in which paclitaxel was administered at the relatively high dose of 250 mg/m2 during a 3-hour infusion. G-CSF was administered daily subcutaneously (s.c.) on days 2 to 19 following chemotherapy. Analysis of paclitaxel and metabolite concentrations was performed by a new highly sensitive reversed-phase high performance liquid chromato-graphic (HPLC) assay. Results: The dose-limiting toxicity in this study was cumulative neurotoxicity. One patient had a partial response and 2 patients had mixed responses of their skin metastases.Relatively low peak plasma concentration (Cmax) with mean values of 6.91 μmol/L (range 3.08 to 8.98) and area under the plasma concentration time curve (AUC), with mean values of 27.04 μmol/L.h (range 14.88 to 40.57), were observed. The total body clearance was 16.99 L/h (range, 10.25 to 27.39). The pharmacokinetic parameter for the prediction of leuko-neutropenia, the duration of the plasma concentration above the threshold of 0.1 μmol/L (T>0.1 μM), was 19.72 h (range 10.54 to 26.31). The three major metabolites detected in human plasma were identified as 6-α-hydroxy-paclitaxel, 3′-p-hydroxypaclitaxel and 6-α,3′-p-dihydroxy-paclitaxel. Cmax and AUC values of these metabolites are reported. Conclusions: The three main metabolic products of paclitaxel in human plasma are 6-α-hydroxypaclitaxel, 3′-p-hydroxypaclitaxel and the dihydroxymetabolite 6-a,3′-p-di-hydroxypaclitaxel. Two patients with liver function disturbances showed a tendency to higher paclitaxel and 6-ct-hydroxypaclitaxel AUC levels, with more pronounced neuropathy.

KW - Anthracycline

KW - Breast cancer

KW - Hydroxylated metabolites

KW - Paclitaxel (Taxol®)

KW - Pharmacokinetics

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=0029066160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029066160&partnerID=8YFLogxK

M3 - Article

C2 - 8664192

AN - SCOPUS:0029066160

VL - 6

SP - 699

EP - 704

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -